Seaport Therapeutics, Inc.

corporate_fare Company Profile

Seaport Therapeutics, Inc.

SPTX·NASDAQ·Life Sciences·CIK 0002042347

Seaport Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company focused on developing new neuropsychiatric medicines. The company creates therapeutic candidates for conditions like depression and anxiety disorders. Its proprietary Glyph technology platform is central to its development efforts. This platform is designed to improve oral bioavailability, bypass first-pass metabolism, and reduce liver enzyme elevations, hepatotoxicity, and other side effects. All therapeutic candidates currently in development utilize this Glyph platform, with research and development activities specifically targeting neuropsychiatric medicines. Seaport Therapeutics, Inc. serves clinicians and key opinion leaders within the healthcare and neuropsychiatric medicine sectors. The company was founded in 2024 and is headquartered in Boston, Massachusetts.

Seaport Therapeutics, Inc. (NASDAQ:SPTX) is a publicly traded company in the Life Sciences sector. Wiseek monitors SPTX SEC EDGAR filings and licensed market news in real time, scoring each submission for market-moving significance on a 1–10 scale. Items rated 7 or higher generate instant alerts.

Recent high-impact activity:

Seaport Therapeutics Reports Q1 Results, Confirms IPO Proceeds Extend Cash Runway into 2029 (2026-06-08)
Seaport Therapeutics Reports Strong Q1, Extends Cash Runway to 2029, and Appoints Biotech Veteran to Board (2026-06-08)
Seaport Therapeutics Reports Strong Q1, Extends Cash Runway to 2029, Advances Clinical Pipeline (2026-06-08)
General Atlantic Discloses 11.5% Stake in Seaport Therapeutics Following IPO Participation (2026-05-11)
ARCH Venture Partners Discloses 11.9% Stake in Seaport Therapeutics Post-IPO, Including $19.8M IPO Purchase (2026-05-06)

Dilution Risk

Low risk

Filing-implied dilution signals for SPTX, detected from its recent SEC filings · latest filing 2026-05-01.

1 recent capital raise

Initial Public Offering Priced · Significant Capital Raised

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with S →

show_chartPrice Chart

Loading chart...

feed SPTX - Latest Insights

Filing Type

Date Range

SPTX

Jun 08, 2026, 7:15 AM EDT

Filing Type: 10-Q

Importance Score:

Seaport Therapeutics Reports Q1 Results, Confirms IPO Proceeds Extend Cash Runway into 2029

Price at Filing: $16.44

Real-time Price: $18.17

Change: +$1.73 (+11%)

Market Cap: $972.65M

Sentiment: Positive

View Wiseek Article

SPTX

Jun 08, 2026, 7:11 AM EDT

Filing Type: 8-K

Importance Score:

Seaport Therapeutics Reports Strong Q1, Extends Cash Runway to 2029, and Appoints Biotech Veteran to Board

Price at Filing: $16.44

Real-time Price: $18.17

Change: +$1.73 (+11%)

Market Cap: $972.65M

Sentiment: Positive

View Wiseek Article

SPTX

Jun 08, 2026, 7:05 AM EDT

Source: Dow Jones Newswires

Importance Score:

Seaport Therapeutics Reports Strong Q1, Extends Cash Runway to 2029, Advances Clinical Pipeline

Price at Filing: $16.44

Real-time Price: $18.17

Change: +$1.73 (+11%)

Market Cap: $972.65M

Sentiment: Positive

View Wiseek Article

SPTX

May 11, 2026, 7:54 PM EDT

Filing Type: SCHEDULE 13D

Importance Score:

General Atlantic Discloses 11.5% Stake in Seaport Therapeutics Following IPO Participation

Price at Filing: $15.25

Real-time Price: $18.17

Change: +$2.92 (+19%)

Market Cap: $972.65M

Sentiment: Positive

View Wiseek Article

SPTX

May 06, 2026, 4:26 PM EDT

Filing Type: SCHEDULE 13D

Importance Score:

ARCH Venture Partners Discloses 11.9% Stake in Seaport Therapeutics Post-IPO, Including $19.8M IPO Purchase

Price at Filing: $16.00

Real-time Price: $18.17

Change: +$2.17 (+14%)

Market Cap: $972.65M

Sentiment: Positive

View Wiseek Article

SPTX

May 04, 2026, 6:02 PM EDT

Filing Type: 4

Importance Score:

ARCH Venture Partners Makes $19.8M Open Market Purchase in Seaport Therapeutics Post-IPO, Signaling Strong Confidence

Price at Filing: $16.70

Real-time Price: $18.17

Change: +$1.47 (+9%)

Market Cap: $972.65M

Sentiment: Positive

View Wiseek Article

SPTX

May 01, 2026, 5:31 PM EDT

Filing Type: 424B4

Importance Score:

Seaport Therapeutics Prices Initial Public Offering at $18.00 Per Share, Raising $254.88 Million for Clinical Development

Price at Filing: $19.78

Real-time Price: $18.17

Change: -$1.61 (-8%)

Market Cap: $972.65M

Sentiment: Positive

View Wiseek Article

SPTX

Apr 30, 2026, 9:58 PM EDT

Source: Dow Jones Newswires

Importance Score:

Seaport Therapeutics Prices Upsized IPO, Signaling Strong Market Demand

Price at Filing: N/A

Real-time Price: $18.17

Change: N/A

Market Cap: $972.65M

Sentiment: Positive

View Wiseek Article

corporate_fare Company Profile